AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10705622
Drug: Short-term hormone
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term hormone replacement therapy (< 10 months)
Trial: 10705622
Drug: Long-term hormone
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term hormone replacement therapy (> 11 months)
Trial: 1746257
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml normal saline solution
Trial: 1746257
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml normal saline solution
Trial: 1746257
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml normal saline solution
Trial: 1746257
Drug: Oxytocin 10
RxNorm normalized name: oxytocin 10 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 units in 20 ml saline solution
Trial: 1746257
Drug: Oxytocin 10
RxNorm normalized name: oxytocin 10 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin 10 units in 40 ml saline solution
Trial: 7064040
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of lignocaine
Trial: 31367893
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy + Balneotherapy (PT + BT)
Trial: 31367893
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy alone (PT)
Trial: 28805022
Drug: Hesperidin 500
RxNorm normalized name: Ascorbic Acid/Bioflavonoid/Hesperidin 500 MG-100 MG-100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hesperidin 500 mg/day for 6 weeks
Trial: 25622744
Drug: Dexmedetomidine preconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine preconditioning (Pre-Dex group) - intravenous infusion at a dose of 0.125 ml/kg (4 µg/ml) for 10 minutes before tourniquet use.
Trial: 3737040
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment before repeat cytology
Trial: 17900705
Drug: n-3 PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFAs (EPA+DHA) 3 g daily for 3 months
Trial: 11895159
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (enteral and parenteral)
Trial: 2671220
Drug: Oxymetazoline (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline (doses and concentrations traditionally used)
Trial: 28431060
Drug: Chronic antiarrhythmic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic antiarrhythmic drug (AAD) therapy with bisoprolol (5 mg od) and/or diltiazem (120-300 mg od)
Trial: 28431060
Drug: Chronic antiarrhythmic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic antiarrhythmic drug (AAD) therapy
Trial: 25288674
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (INI) 40 IU
Trial: 23117071
Drug: Trabectedin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.5 mg/m² (24‐h infusion every 3 weeks)
Trial: 17100937
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg (2 x 50 mg encapsulated tablets)
Trial: 15149510
Drug: Inositol supplements
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inositol supplements
Trial: 11522873
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous iron infusions (200 mg every 2 months)
Trial: 11522873
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral iron supplements (210 mg elemental iron per day)
Trial: 9050955
Drug: Mitoxantrone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (8 mg/m2 I.V. infusion every month for 1 year)
Trial: 9050955
Drug: Placebo (I.V.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (I.V. infusion of saline every month for 1 year)
Trial: 30640245
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol (3 mg/kg)
Trial: 30640245
Drug: Peritonsillar infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonsillar infiltration with bupivacaine (5 ml, 0.25%)
Trial: 26643993
Drug: GSK1278863 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 50 mg
Trial: 26643993
Drug: GSK1278863 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 100 mg
Trial: 26643993
Drug: GSK1278863 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1278863 (10 to 100 mg)
Trial: 23821414
Drug: Riluzole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (50 or 100 mg/day based on bodyweight) + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Trial: 23821414
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Risperidone (up to 2 or 3 mg/day based on bodyweight)
Trial: 7923646
Drug: Hirudin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hirudin (0.4 mg/kg body wt bolus and 0.15 mg.kg‐1.h‐1) infused over 48 to 72 hours
Trial: 7923646
Drug: Heparin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (70 IU/kg body wt bolus and 15 IU.kg‐1.h‐1) infused over 48 to 72 hours
Trial: 3347519
Drug: Vasoactive drugs
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasoactive drugs or mechanical ventilation
Trial: 3347519
Drug: Cardiac index
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac index less than 2.3 L/min/m2
Trial: 28499707
Drug: L‐SMILE (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐SMILE (low energy: 100, 105, and 110 nJ)
Trial: 20881376
Drug: Erythromycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (125 mg, three times/day)
Trial: 18245068
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous patient-controlled analgesia (PCA)
Trial: 17001944
Drug: Urgotul wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urgotul wound dressing with TNP therapy
Trial: 1598464
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg acetylsalicylic acid
Trial: 1598464
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg acetylsalicylic acid plus 75 mg dipyridamole
Trial: 2856892
Drug: Nadolol 10
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol 10 mg
Trial: 30160168
Drug: BMAC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMAC injection
Trial: 22350194
Drug: Long-term Internet-delivered
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term Internet-delivered worksite health promotion programme with additional website functionalities (action-oriented feedback, self-monitoring, possibility to ask questions, monthly e-mail messages)
Trial: 19126830
Drug: Instalment prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instalment prescription (n = 101)
Trial: 19126830
Drug: Normal prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal prescription (n = 103)
Trial: 14747671
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily iron supplementation
Trial: 14747671
Drug: Mebendazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (500 mg) every 3 months
Trial: 8993242
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (group B)
Trial: 27181129
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment based on TCM diagnosis
Trial: 23354913
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care treatment
Trial: 15879586
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic drugs (olanzapine, perospirone, quetiapine, or risperidone)
Trial: 12939003
Drug: Mandibular implant-retained
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandibular implant-retained overdenture (IOD)
Trial: 10930055
Drug: Sodium polystyrene
RxNorm normalized name: Sodium Polystyrene Sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium polystyrene sulfonate 30 g
Trial: 8689424
Drug: Interleukin-6 (IL-6)
RxNorm normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-6 (IL-6) daily bolus therapy
Trial: 8689424
Drug: Interleukin-6 (IL-6)
RxNorm normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-6 (IL-6) continuous infusion (C.I.) therapy
Trial: 8689424
Drug: Interleukin-6 (IL-6)
RxNorm normalized name: autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells)
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-6 (IL-6) bolus therapy
Trial: 31553410
Drug: Inclisiran (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (1 dose: 200, 300, or 500 mg on day 1)
Trial: 31553410
Drug: Inclisiran (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (2 doses: 100, 200, or 300 mg on days 1 and 90)
Trial: 31553410
Drug: Inclisiran (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (2 doses: 300 mg)
Trial: 31553410
Drug: Inclisiran (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (1 or 2 doses)
Trial: 29235159
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea ointment
Trial: 22506760
Drug: Higher energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher energy treatment with cryogen spray cooling (CSC) (10‐mm spot size; 50 J/cm(2); 50‐ms pulse duration and CSC settings of 30‐ms duration with a 20‐ms delay)
Trial: 22506760
Drug: Lower energy
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower energy treatment with no CSC (10 mm; 20 J/cm(2); 50 ms)
Trial: 17506788
Drug: Concurrent oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent oxytocin infusion with dinoprostone pessary
Trial: 12082182
Drug: Treatment using
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment using computer support to train patients to eat and recognize satiety, with physical activity restriction and resting in a warm room after eating.
Trial: 12082182
Drug: Treatment to
RxNorm normalized name: Lice Treatment Topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment to remission.
Trial: 6626409
Drug: Rectal solution
RxNorm normalized name: Rectal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal solution including diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Trial: 29779922
Drug: IM-HA/D (Intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM-HA/D (Intramuscular injection of Fluvax® 2016), n=15
Trial: 24464551
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sofosbuvir and GS-0938
Trial: 19558807
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose ACTH therapy (50 IU per day for 2 weeks, then tapered to zero over 2 weeks)
Trial: 19558807
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ACTH therapy (0.4 IU/kg per day for 2 weeks, then tapered to zero over 2 weeks; dosage increased to 1 IU/kg per day if no effective response)
Trial: 19558807
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose ACTH therapy
Trial: 19558807
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ACTH therapy
Trial: 19558807
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Conventional and Low dose ACTH therapy)
Trial: 11339019
Drug: Hyperthyroid patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthyroid patients (pre-treatment)
Trial: 11339019
Drug: Hyperthyroid patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthyroid patients (post-treatment)
Trial: 8783690
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg on days 1‐5 and 10 (total dose, 24 mg/kg)
Trial: 8783690
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg on days 1‐5 and 10 (total dose, 18 mg/kg)
Trial: 8783690
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg on days 1‐4 and 10 (total dose, 15 mg/kg)
Trial: 8783690
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg for 10 days
Trial: 8783690
Drug: 12 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/kg total dose
Trial: 6714287
Drug: Hydergine special
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine special (1 x 4 mg)
Trial: 6714287
Drug: Hydergine forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine forte (2 x 2 mg)
Trial: 25840767
Drug: Nebulized fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized fentanyl (2 μg/kg)
Trial: 23123043
Drug: Specific medical
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific medical food (400 ml daily for one week, high in protein and leucine, enriched with fish oil and specific oligosaccharides)
Trial: 18206175
Drug: Folate treatment
RxNorm normalized name: folate
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folate treatment (5 mg folic acid per day, 50 mg vitamin B6 per day, 1,000 microg vitamin B12 per day)
Trial: 11083735
Drug: Metoprolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol treatment for 12 months
Trial: 8866582
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray ad libitum (n=45)
Trial: 8866582
Drug: Nicotine nasal
RxNorm normalized name: nicotine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine nasal spray fixed dosage of 1 mg x h‐1 during the day (n=44)
Trial: 1503915
Drug: Mitozantrone, 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitozantrone, 14 mg m‐2 intravenously every 3 weeks (n = 30)
Trial: 1503915
Drug: Megesterol acetate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Megesterol acetate, 160 mg bd (n = 30)
Trial: 6510459
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with terbutaline (Theophylline)
Trial: 6510459
Drug: Combination with
RxNorm normalized name: Iron in combination with folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination with terbutaline (Enprofylline)
Trial: 31422671
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (EPA+DHA) at a dose of 4 g/d
Trial: 31422671
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (EPA only) at a dose of 4 g/d
Trial: 31422671
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (4 g/d)
Trial: 31422671
Drug: EPA-only (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-only (4 g/d) in REDUCE-IT trial
Trial: 27075874
Drug: Interceptor LN
RxNorm normalized name: INTERCEPTOR
DrugBank: Milbemycin oxime (DB11531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interceptor LN (200 mg/m(2) alpha‐cypermethrin)
Trial: 27075874
Drug: Conventional treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional treated nets (CTN) (40 mg/m(2) alpha‐cypermethrin)
Trial: 17519148
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (OC) providing levonorgestrel (LNG) and ethinyl estradiol (EE) (150/30 microg per tablet)
Trial: 9034228
Drug: NOCTE (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOCTE (1 x 30 mg at 21.00 h)
Trial: 9034228
Drug: BID (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID (15 mg at 21.00 h and 15 mg at 09.00 h)
Trial: 8379508
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg beta-carotene, 900 mg vitamin C, and 200 mg alpha-tocopherol for 6 months
Trial: 8379508
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vitamin supplements)
Trial: 3092836
Drug: CS-514 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-514 (20 mg twice a day for 7 days)
Trial: 3092836
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice a day for 7 days)
Trial: 30151705
Drug: Mechanical debridement,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical debridement, 0.12% chlorhexidine mouthwash, and Lactobacillus reuteri (probiotic agent)
Trial: 28848182
Drug: G‐CSF given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF given during all 6 chemotherapy cycles
Trial: 28848182
Drug: G‐CSF limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF limited to the first 2 chemotherapy cycles
Trial: 22654449
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate (15 mg) with 2 L PEG solution
Trial: 22654449
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 2 L PEG solution
Trial: 22654449
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate (15 mg) with 2 L PEG solution (after excluding severe constipation)
Trial: 22654449
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 2 L PEG solution (after excluding severe constipation)
Trial: 22654449
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosapride citrate (15 mg) with 2 L PEG solution (among previous colonoscopy experience subgroup)
Trial: 11311761
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir from 36 weeks of gestation to term (group 1)
Trial: 7543272
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of strontium (89)
Trial: 7543272
Drug: Single large
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single large treatments
Trial: 7543272
Drug: Extended courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended courses of treatment
Trial: 21693215
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg orally twice daily from day 0 to 7 postoperatively
Trial: 8974126
Drug: Glutamine-supplemented total
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-supplemented total parenteral nutrition (TPN)
Trial: 1451930
Drug: sultamicillin 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sultamicillin 750 mg/day (n = 9)
Trial: 1451930
Drug: sultamicillin 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sultamicillin 1500 mg/day (n = 46)